Pegipanermin is under clinical development by Inmune Bio and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pegipanermin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pegipanermin overview

Pegipanermin (INB-03) is under development for the treatment of Alzheimer's disease, mild cognitive impairment, amyotrophic lateral sclerosis (ALS), multiple sclerosis, breast cancer, non-small cell lung cancer, malignant melanoma, treatment resistant depression, epithelial cancer, kidney cancer, upper or lower gastrointestinal tract cancer includes anal cancer, colorectal cancer, stomach cancer, esophageal cancer, duodenal, ileum cancer, HER2+ breast cancer and other solid tumors that have failed multiple lines of therapy. It was also under development for complications of cytokine storm caused by COVID-19. The drug candidate is administered as a once-a-week subcutaneous injection. It is a TNFR1 inhibitor that targets myeloid-derived suppressor cells (MDSC). It was also under development for the treatment of Parkinson’s disease, metastatic epithelial cancer, depression, Huntington's disease, autoimmune and neuroinflammatory diseases including rheumatoid arthritis, asthma, uveitis and Crohn's disease.

Inmune Bio overview

Inmune Bio is a clinical stage biotechnology company. It develops novel immunotherapies to treat the cancer. The company’s product portfolio includes INKmune, a biologic delivery system which allows delivery of essential priming signals to patients’ resting NK cells; INB03 is a protein biologic inhibitor, for the treatment of cancer; XPro1595, a protein biologic that targets soluble TNF (sTNF) in Alzheimer’s disease and NeuLiv, for the treatment of nonalcoholic steatohepatitis. It serves in the therapeutic areas of tumor cells, immune system. It offers products under Inkmune and NeuLiv brand names. The company has operations in the US. Inmune Bio is headquartered in La Jolla, California, the US.

For a complete picture of Pegipanermin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.